

BD to invest \$35 M in US facility to expand prefilled flush syringe manufacturing

05 August 2025 | News

Adding approximately 50 new jobs to expand prefilled flush syringe manufacturing at Nebraska facility



BD (Becton, Dickinson and Company), a leading global medical technology company, has announced plans to invest more than \$35 million and add approximately 50 new jobs to expand prefilled flush syringe manufacturing at its Columbus, Nebraska facility to increase the resiliency of the US healthcare system.

The investments will support new BD® PosiFlush™ Prefilled Flush Syringe production lines, product innovation and operational efficiencies, enabling BD to produce hundreds of millions of additional units annually to meet growing demand from US hospitals and health systems.

Prefilled flush devices like PosiFlush™ Prefilled Flush Syringes are used in nearly every hospital across the country as part of catheter care and maintenance to help prevent catheter-related complications and support efficient, high-quality patient care. Quality in manufacturing is critical as these devices deliver fluid directly into a patient's bloodstream, where any contamination or defect can have serious, even fatal, consequences.

PosiFlush™ Prefilled Flush Syringes are manufactured using a fully automated, hands-free process, ensuring that the first person to touch the syringe is the clinician – helping to reduce the potential for contamination. Every syringe is inspected using a rigorous, multi-step, end-to-end inspection process to meet high quality standards for patients and providers.

Over the past three years, BD has invested more than \$80 million to expand BD PosiFlush™ capacity, increasing U.S. production by more than 750 million units, including a 10% increase this year alone. The company's facility in Columbus is

the largest manufacturer of prefilled flush devices in the US and has been operating for more than 75 years.